Literature DB >> 11981366

Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study.

Lynn M Kirstein1, Ruth M Greenblatt, Kathryn Anastos, Alexandra Levine, Audrey L French, Howard Minkoff, Sylvia Silver, Stephen J Gange.   

Abstract

OBJECTIVE: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time, the extent to which individuals switch, and the characteristics of those who are switching.
METHODS: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models, and compared disease markers among women switching or remaining on unchanged HAART regimens.
RESULTS: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar, with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37% in September 2000), although the percentage discontinuing therapy altogether increased 2-fold.
CONCLUSION: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981366     DOI: 10.1097/00126334-200204150-00010

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

Review 1.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.

Authors:  David N Feldman; Joseph G Feldman; Ruth Greenblatt; Kathryn Anastos; Leigh Pearce; Mardge Cohen; Stephen Gange; Suzanne Leanza; Robbie Burk
Journal:  AIDS Educ Prev       Date:  2009-06

3.  Treatment switching in South Indian patients on HAART: what are the predictors and consequences?

Authors:  Sara Chandy; Girija Singh; Elsa Heylen; Monica Gandhi; Maria L Ekstrand
Journal:  AIDS Care       Date:  2011-05

4.  Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.

Authors:  Michael J Silverberg; Michael F Schneider; Barbara Silver; Kathryn M Anastos; Robert D Burk; Howard Minkoff; Joel Palefsky; Alexandra M Levine; Raphael P Viscidi
Journal:  Clin Vaccine Immunol       Date:  2006-04

5.  Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study.

Authors:  Joseph G Feldman; Howard Minkoff; Michael F Schneider; Stephen J Gange; Mardge Cohen; D Heather Watts; Monica Gandhi; Robert S Mocharnuk; Kathryn Anastos
Journal:  Am J Public Health       Date:  2006-05-02       Impact factor: 9.308

6.  Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.

Authors:  Daniel J Merenstein; Michael F Schneider; Christopher Cox; Rebecca Schwartz; Kathleen Weber; Esther Robison; Monica Gandhi; Jean Richardson; Michael W Plankey
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

7.  Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.

Authors:  Michael J Silverberg; Mary Elizabeth Gore; Audrey L French; Monica Gandhi; Marshall J Glesby; Andrea Kovacs; Tracey E Wilson; Mary A Young; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2004-08-16       Impact factor: 9.079

8.  An instrumental variables evaluation of the effect of antidepressant use on employment among HIV-infected women using antiretroviral therapy in the United States: 1996-2004.

Authors:  Omar Galárraga; David S Salkever; Judith A Cook; Stephen J Gange
Journal:  Health Econ       Date:  2010-02       Impact factor: 3.046

9.  Assessing the performance of a computer-based policy model of HIV and AIDS.

Authors:  Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

10.  Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

Authors:  John D Morris; Elizabeth T Golub; Shruti H Mehta; Lisa P Jacobson; Stephen J Gange
Journal:  AIDS Res Ther       Date:  2007-06-06       Impact factor: 2.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.